期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (5)
N-6-methyladenosine (m(6)A) modifications control multifaceted RNA metabolism and are one of the most extensively distributed modifications on the hum......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (6)
Background: The role and mechanism of long non-coding RNA cytoskeleton regulator (CYTOR) in Invasive Pituitary Adenomas (IPA) have not been elucidated......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (4)
Drug resistance is the major reason accounting for the treatment failure in cancer chemotherapy. Dysregulation of the epigenetic machineries is known ......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (3)
Background: High risk type 16 of human papillomavirus (HPV16) is associated with 50% of cervical cancer, for which reliable targeted therapies are lac......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (3)
Background: Esophageal squamous cell carcinoma (ESCC) is a major subtype of esophageal cancers. The five-year survival rate of ESCC is low, and molecu......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (3)
Background: The major challenge to the treatment of advanced colorectal cancer (CRC) is the persistent occurrence of chemoresistance. One of the estab......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (3)
Background: CYP1B1 is considered as a valuable target for chemotherapy. It catalyzes the bioactivation of naphthoquinone oximes within certain cancer ......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (1)
Background: Abnormal spindle-like microcephaly-associated protein (ASPM) has been implicated in the aggressive behavior of several malignant tumors. H......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (1)
CYP1A1 and CYP1B1 are extrahepatic P450 family members involved in the metabolism of procarcinogens, such as PAHs, heterocyclic amines and halogen-con......
期刊： CURRENT CANCER DRUG TARGETS, 2021; 21 (2)
Tumor recurrence and drug resistance are two of the key factors affecting the prognosis of cancer patients. Cancer stem cells (CSCs) are a group of ce......
期刊： CURRENT CANCER DRUG TARGETS, 2020; 20 (1)
Background: Forkhead box C1 (FOXC1) is an important cancer-associated gene in tumor. PPAR-gamma and C/EBP alpha are both transcriptional regulators in......
期刊： CURRENT CANCER DRUG TARGETS, 2020; 20 (1)
The vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) signaling pathway is one of the most important pathways responsible for tumor a......
期刊： CURRENT CANCER DRUG TARGETS, 2020; 20 (10)
Background: Many studies have explored the relationship between the expression level of miRNAs and the prognosis of patients with laryngeal cancer (LC......
期刊： CURRENT CANCER DRUG TARGETS, 2020; 20 (10)
The clinical pathology of various human malignancies is supported by tropomyosin receptor kinase (Trk) B TrkB which is a specific binding receptor of ......
期刊： CURRENT CANCER DRUG TARGETS, 2020; 20 (10)
Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide neoantigens for immunotherapy. Here, we summarize recent......
